Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesCompany achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare ConferenceWALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New York City.
Ardelyx Responds to District Court Decision Granting Motion to DismissInclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk
Ardelyx to Participate at the 2024 Jefferies London Healthcare ConferenceWALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London.
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business UpdateIBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney WeekWALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the American Society of Nephrology’s (ASN) Kidney Week, currently taking place in San Diego. Ardelyx is also hosting an Exhibitor Spotlight discussing hyperphosphatemia management.
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (
NASDAQARDX) on behalf of long-term stockholders following a class action complaint that was filed against Ardelyx on August 16, 2024, with a Class Period from October 31, 2023 to July 1, 2024. Our investigation concerns whether the board of directors of Ardelyx have breached their fiduciary duties to the company.
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient CommunityWALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx’s director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (
NASDAQARDX) and reminds investors of the October 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney WeekWALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH® (tenapanor) will be presented at the American Society of Nephrology’s (ASN) Kidney Week, to be held October 24-27, 2024, in San Diego.
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers and acquirers of securities of Ardelyx, Inc. (
NASDAQARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”). Ardelyx describes itself as a “biotechnology company focused on developing and commercializing therapies for, among other things, patients with chronic kidney disease (“CKD”).”
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ArdelyxFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ardelyx To Contact Him Directly To Discuss Their Options
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental GastroenterologyWALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recent publication of a review article, titled “Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome With Constipation in the United States” in Clinical and Experimental Gastroenterology, an international, peer reviewed, open access journal focusing on all aspects of gastroenterology research, as well as clinical results in human, animal and in vitro studies that shed light on disease processes and potential new therapies.
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Nano Ardelyx, Inc. (ARDX) Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Ardelyx, Inc. (“Ardelyx” or the “Company”) (
NASDAQARDX) securities during the period of October 31, 2023 to July 1, 2024, inclusive (“the Class Period”). Investors have until October 15, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
